Drugs.com
JUNE 1, 2024
SATURDAY, June 1, 2024 -- Can mindfulness meditation be good medicine for both mental and physical ills? Yes, says one expert who explains the practice and what conditions it might help. A particular form of mindfulness that focuses on pleasure.
Drug Patent Watch
JUNE 1, 2024
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Slovakia.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Perficient: Drug Development
JUNE 1, 2024
Permission sets in Salesforce are a powerful tool for granting users access to specific objects, fields, and functionality without modifying their profiles. However, testing permission sets is crucial to ensure they are working as intended and not causing any unintended consequences. Let’s discuss when and how to test permission sets, as well as some advanced techniques for more thorough testing. 1.
Drug Patent Watch
JUNE 1, 2024
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five… Source
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Perficient: Drug Development
JUNE 1, 2024
As a Salesforce Admin, delivering projects on time and ensuring user adoption is crucial. However, one of the biggest challenges is getting User Acceptance Testing (UAT) right. Ineffective UAT can lead to costly delays, frustrated users, and even failed deployments. By focusing on these key areas, you can create a comprehensive UAT plan that validates the application from the end-user perspective and ensures it meets business requirements before going live.
Drug Patent Watch
JUNE 1, 2024
Annual Drug Patent Expirations for NUZYRA Nuzyra is a drug marketed by Paratek Pharms Inc and is included in two NDAs. It is available from one supplier.
Expert insights. Personalized for you.
234 
Let's personalize your content